 SAN DIEGO, Aug. 9, 2021 PRNewswire -- Aethlon Medical, Inc. Nasdaq: AEMD, a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its first quarter ended June 30, 2021 and provided an update on recent developments. Company Updates Aethlon Medical is continuing the research and clinical development of our Hemopurifier to bind and remove COVID-19 viral particles, including many variant COVID-19 particles of interest and related exosomes. 